Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 457 | 2018 |
Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 395 | 2017 |
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 360 | 2016 |
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ... Cancer discovery 7 (9), 999-1005, 2017 | 261 | 2017 |
Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 214 | 2017 |
Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 171 | 2019 |
Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 147 | 2017 |
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 92 | 2022 |
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy H Beltran, AW Wyatt, EC Chedgy, A Donoghue, M Annala, EW Warner, ... Clinical Cancer Research 23 (22), 6802-6811, 2017 | 80 | 2017 |
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 69 | 2021 |
Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 66 | 2020 |
Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 66 | 2020 |
SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA C Kockan, F Hach, I Sarrafi, RH Bell, B McConeghy, K Beja, A Haegert, ... Bioinformatics 33 (1), 26-34, 2017 | 59 | 2017 |
Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ... Clinical Cancer Research 27 (16), 4610-4623, 2021 | 52 | 2021 |
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8: 444–457. doi: 10.1158/2159-8290 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 50 | |
A randomized phase II cross-over study of abiraterone+ prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). KN Chi, M Annala, K Sunderland, D Khalaf, D Finch, CD Oja, J Vergidis, ... Journal of Clinical Oncology 35 (15_suppl), 5002-5002, 2017 | 49 | 2017 |
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 48 | 2021 |
Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer S Taavitsainen, M Annala, E Ledet, K Beja, PJ Miller, M Moses, M Nykter, ... JCO precision oncology 3, 1-9, 2019 | 44 | 2019 |
Genome-wide chemical mapping of O-GlcNAcylated proteins in Drosophila melanogaster TW Liu, M Myschyshyn, DA Sinclair, S Cecioni, K Beja, BM Honda, ... Nature chemical biology 13 (2), 161-167, 2017 | 41 | 2017 |
A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian cancer trials group study IND205 SJ Hotte, KN Chi, AM Joshua, D Tu, RJ Macfarlane, RW Gregg, ... Clinical Genitourinary Cancer 17 (3), 201-208. e1, 2019 | 33 | 2019 |